The "clinically meaningful" debate around CDR-SB is not settling

The two FDA-approved anti-amyloid antibodies achieved statistically significant slowing of decline on the Clinical Dementia Rating - Sum of Boxes (CDR-SB) endpoint in their pivotal trials. The deltas were measurable but small in absolute terms - sub-half-point on a scale where individual patient trajectories vary considerably. For a plain-language overview of what CDR-SB is and what a small change on it represents, see our explainer on CDR-SB.

The debate that continues - and is not settling - is about clinical meaningfulness. The arguments break down predictably:

• One view holds that the absolute deltas are too small to reliably translate into perceived day-to-day benefit for an individual patient, and that the population-level signal does not justify the operational and safety cost.
• The opposing view holds that CDR-SB slowing in the early symptomatic window is the most disease-relevant outcome currently measurable, and that even modest preserved function meaningfully matters across the cumulative course.
• A middle view treats the existing approvals as a foundation but argues that future trials need to pair CDR-SB with patient-centered outcomes that are easier to communicate.

The debate matters operationally because it shapes how trial readouts for next-generation programs - tau-directed antibodies, GLP-1 mechanisms, combination regimens - will be received. A program that hits statistical significance with a similar absolute effect size will face the same interpretive argument.

We are watching: FDA advisory committee framing of next-cycle approvals, payer policy language around "clinically meaningful benefit," and the patient-reported outcome measures being incorporated into late-stage trial designs.